CRY1 and cancer: PTEN alterations have been previously described in cSCC9 (Supplementary Data 13), but the other SMGs including FLNB, GLIS3, CACNA1C, HERC6, TRAPPC9, MAPK1P1L (Fig. 3b, Supplementary Fig. 7 and Supplementary Data 15), GRHL2, CLCN3, TMEM51, ATP1A1, LCLAT1 and CRY1 (Fig. 3b, Supplementary Fig. 8 and Supplementary Data 16) are of unknown significance in cancer and present with no obvious hotspot mutations.